Vahid Tohidi
Neurology · Orlando, FLNPI 1356766786
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $923, more than ten times the $31 reported in 2021.
Across 126 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$511
- Biogen$301
- EDW Pharma, Inc.$268
- AstraZeneca$206
- Catalyst Pharmaceuticals, Inc.$203
- Argenx US, Inc.$163
- plus $1K from 22 others
Across 9 payments — averaging $49,480 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$368K
- Novartis$43K
- Catalyst Pharmaceuticals, Inc.$34K
What the payments were for
- Food & beverage$2,87496%
- Education$1124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $511 |
| Biogen | 15 | $301 |
| EDW Pharma, Inc. | 1 | $268 |
| AstraZeneca | 8 | $206 |
| Catalyst Pharmaceuticals, Inc. | 8 | $203 |
| Argenx US, Inc. | 9 | $163 |
| Genentech USA, Inc. | 8 | $157 |
| Acadia Pharmaceuticals Inc | 7 | $139 |
| Tanabe Pharma America, Inc. | 7 | $136 |
| Amgen | 5 | $123 |
| ITF Therapeutics LLC | 2 | $113 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Alnylam Pharmaceuticals Inc. | 3 | $78 |
| Grifols USA, LLC | 4 | $73 |
| Lilly USA, LLC | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Sanofi | 2 | $48 |
| CSL Behring | 2 | $48 |
| UCB, Inc. | 1 | $45 |
| GRT US Holding, Inc. | 1 | $24 |
| Insightec,inc | 1 | $21 |
| Pfizer | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Aucta Pharmaceuticals, Inc. | 2 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tiglutik$268
How this compares
$2,986 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 13 | $858,669 |
| Radicava OrsEdaravone | 37 | $528,988 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 18 | $164,737 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 26 | $161,019 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $137,421 |
| NuedextaDextromethorphan Hbr/Quinidine | 19 | $31,812 |
| Riluzole | 62 | $8,142 |
| Mycophenolate Mofetil | 18 | $1,892 |
| Pyridostigmine Bromide | 16 | $1,688 |
| Gabapentin | 80 | $1,251 |
| Baclofen | 32 | $426 |
| Sodium Chloride0.9 % Sodium Chloride | 20 | $120 |
| Duloxetine Hcl | 12 | $109 |
| Prednisone | 19 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $203 | $858,66913 claims |
| PfizerPanzyga | $20 | $161,01926 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $58 | $137,42117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,434 neurology providers in Florida.
Other neurology in Orlando
- Ramon Rodriguez CruzOrlando$1M
- Mark KlafterOrlando$247K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.